Metyrapone is known to stimulate the release of ACTH by a negative feedback mechanism of cortisol and widely used for testing the hypothalamo-pituitary axis. In the previous study (Kunita et al., 1970) , we reported an oral administration of 1.5g of metyrapone induced an increase in plasma GH levels in normal subjects. Since the rise in plasma GH was not suppressed in the subjects pretreated with dexamethasone, it was considered that the response of GH might not be related to a negative feedback mechanism through which metyrapone stimulated ACTH release. In order to conclude the pos- metyrapone orally at 9:00 a.m. One week later, 2 out of the 6 subjects and other 4 subjects received 1.5g of metyrapone in the same manner. They were at bed rest for 30 min before and throughout the study. Thirty min prior to the initiation of blood sampling, an indwelling needle was inserted into a forearm vein. Blood samples for the estimation of plasma ACTH, GH and cortisol were obtained immediately before and every 30 min for 4 hr following. Plasma ACTH was measured by a radioimmunoassay according to Berson and Yalow (1968) . The minimal detectable dose of ACTH was as low as 2.5pg/tube in this assay system. Plasma GH was determined by a double antibody radioimmunoassay (Schalch and Parker, 1964) and plasma cortisol by the method of Rudd et al.(1963) . For the evaluation of plasma GH response, an increase in plasma GH levels of 5.0ng/ml above the base line considered to be a positive response. spectively. Plasma cortisol levels at 90 min was not significantly different between both groups. The similar side effects appeared after 1.5g of metyrapone, as we observed previously (Kunita et al., 1970) , but they were less or none after 1.0g of metyrapone. Each individual data of plasma ACTH and GH levels after either 1.0 or 1.5g of metyrapone is reported in Tables 1 and 2 . The responses of plasma ACTH to 1.0g of metyrapone were not uniform. In Subject 1 an initial rise in plasma ACTH appeared at 60 min and a second small peak at 180 min. A similar sharp peak was observed in Subject 2 at 90 min and then rapidly decreased at 150 min. On the contrary, plasma ACTH levels decreased in Subjects 3 and 5 during the first 90 min, and increased at 240 min in Subjects 3. No clear changes in plasma ACTH levels were observed in Subjects 4 and 6. Summerizing these individual observations, there is no consistent tendency in the levels of plasma ACTH after 1.0g of metyrapone (Table 1 ).The response of plasma GH to 1.0g of metyrapone was seen in Subjects 2 and 5 (Table 2 ). In Subject 2 plasma GH peak was preceded by that of plasma ACTH, but no rise in plasma ACTH was observed in Subject 5. When 1.5g of metyrapone was given, plasma ACTH levels increased in all subjects (Table 1) . The magnitudes and the patterns of ACTH responses were different in each subject. An initial sharp rise in plasma ACTH was seen within 90min in all subjects except Subject 8 in whom the level increased gradually to a maximal level at 120 min. The responses of plasma ACTH to 1.5g of metyrapone were similar in fashion to those to 1.0g of metyrapone in Subjects 1 and 2, to whom the both doses of metyrapone were administered. However, when 1.5g of Table 1 . Effect of an oral administration of either 1.0 or 1.5g of metyrapone on the levels of plasma ACTH Table 2 . Effect of an oral administration of either 1.0 or 1.5 g of metyrapone on the levels of plasma GH Values below 0.5ng/ml were considered as 0.5ng/ml for statistical calculation. metyrapone was given, the level of the second ACTH peak was higher in Subject 1 and the duration of high levels of ACTH was longer in Subject 2 than when 1.0g of metyrapone was given. A statistical analysis indicated that the levels of plasma ACTH increased significantly 60, 90 and 150 min after 1.5g of metyrapone (Table 1) . The GH response to 1.5 g of metyrapone was observed in 5 out of 6 subjects ( Table 2 ). The mean peak value was reached at 90 min. The differences between the values at 0 and 90 min and between those at 0 and 60 min were statistically significant. No relationship was observed between the changes in plasma ACTH and GH.
Discussion
Recently Sawin et al.(1971) reported that a rise in plasma GH levels was not induced 120 min after 1.5g of metyrapone under the similar condition as we previously described (Kunita et al., 1970) . The GH response to metyrapone was reconfirmed in the present study, so that it is difficult to explain their negative results. Two explanations, however, could be possible. First, their subjects must have weighed more than ours, so 1.5g of metyrapone might have not been enough to evoke GH release. The dose of metyrapone per kg body weight in each subject is shown in Tables 1 and 2 . Second, since in the present study a statistically significant increment in plasma GH levels was observed 60 and 90 min after 1.5g of metyrapone, and the value at 120 min was not significantly different. This may suggest that measuring once at 120 min is not enough to evaluate the action of metyrapone.
The present study clearly indicates that GH response to metyrapone is not related to ACTH secretion. This may also exclude the possibility that an increase in endogenous ACTH stimulates GH release, though Zahnd et al.(1969) (Berson and Yalow, 1968) or longer (Berson and Yalow, 1968; Liddle et al., 1962; Strott et al., 1969; Jubiz et al., 1970a, and b) to stimulate the release of ACTH by a negative feedback mechanism. Therefore, the of metyrapone may not be caused by the negative feedback mechanism. There are a few studies measuring the changes in plasma ACTH within a short period when given a single dose of metyrapone orally. Jubiz et al. (1970a) gave a dose of 750mg of metyrapone at 8:00 a.m. and found no change in plasma ACTH levels 3 hr later. A similar observation was made by Berson and Yalow (1968) , who showed that when the same dose of metyrapone was given at 9:00 a.m., plasma ACTH concentration changed little or continued to drop for 2-3 hr. Since only 2 out of 6 subjects responded to 1.0g of metyrapone in this study, a smaller amount of this drug could not evoke the "early rise"in plasma ACTH levels. Considering together with GH and ACTH responses to metyrapone, it is strongly indicated that a higher dose of metyrapone may stimulate the release of both hormones by acting derectly on the pituitary and/or on the hypothalamus within a short period as a non-specific stimulus. The direct effect of metyrapone has been suggested by Ganong and Gold (1960) . A question may arise as to whether or not an increase in plasma ACTH levels after metyrapone reflects the periodic diurnal variation of plasma ACTH reported by Krieger et al.(1971) . To exclude this possibility the control experiment should have been performed. We, however, started our experiments at 9: 00 a.m., when they reported plasma ACTH levels tended to decrease. A similar tendency was observed in 2 subjects who did not respond to 1.0g of metyrapone. Moreover, our results indicate that the stimulatory effect of metyrapone on ACTH release was dose dependent. Therefore, it seems to be possible that metyrapone itself stimulated the release of ACTH.
